Castle Biosciences FY2021 revenue $94.1M (+50% YoY); guides FY2022 $115-120M

CASTLE BIOSCIENCES INC

2021-FY EPS reported -$1.24 revenue$94,085,000

Full-year 2021 revenue $94.1M, up 50% vs $62.6M in 2020; net loss $(31.3)M vs $(10.3)M.
Total GEP test volume 28,118 (+55% YoY); DecisionDx-Melanoma 20,328 (+25%).
Q4 revenue $25.0M (+45% YoY); delivered 8,242 test reports (+60%).
Cash and equivalents $330M at Dec. 31, 2021; adjusted EBITDA $(14.9)M for 2021.
FY2022 revenue expected $115-120M; includes TissueCypher Barrett's esophagus test.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.